Aluminum (Al) Level in Blood and the Risk of Amnestic Mild Cognitive Impairment (AMCI) and Alzheimer's Disease (AD): A Case-Control Study

摘要

Background: Aluminum(AI) is known as a potential environmental neurotoxin substance. Epidemiological studies have found the evidence of an association between aluminum exposure neurodegenerative disorders. Most of the studies tend to emphasize the association between aluminum and Alzheimer's disease(AD), while few studies have been suggesting Serum aluminum could effect on cognitive disorders including mild cognitive impairment. Thus, this study focused on finding out the association between serum aluminum level and amnestic mild cognitive impairment (aMCI) or Alzheimer's disease (AD) Method: A matched case-control study was conducted. 136 aMIC patients and 191 Alzheimer's disease patients were recruited from a university-based hospital from 2014 to 2017. Participants (N=1957) were older than 60 years and were from community based cohorts in Seoul, Incheon, Ganghwa and Wonju, South Korea. Four healthy controls for each aMCI (N=123) patients and AD patients (n=136) were randomly selected using age and sex matching method. Serum aluminum level was analyzed from the collected blood samples. Conditional logistic regression was used, adjusting for age, education level, BMI, total cholesterol, triglyceride, high-density lipoprotein cholesterol, smoking and drinking. Results : The geometric means of aluminum level in the blood was 11.16u.g/L (95%CI 10.04,12.39) in AD patients and was 8.57ug/L (95%CI 8.14, 9.03) in control group. The geometric means of aluminum level was 11.09u.g/L (95%CI 10.20, 12.06) in aMIC group and 8.35ug/L (95%CI 7.91,8.81) in its control group. The odds ratios was 2.77 (1.70-4.58) for aMCI and 2.66(1.64-4.31) for AD. Conclusions: Aluminum level in blood was positively associated with the risk of aMIC and AD.